BioCentury
ARTICLE | Company News

Gilead and GlaxoSmithKline modify deal

January 16, 2001 8:00 AM UTC

GlaxoSmithKline (GSK; LSE:GSK) waived its right to participate in the development and marketing of GILD's NX 211 liposomal lurtotecan in order to obtain FTC clearance for the recently completed merger...